Mehran Attari is a Cardiology physician. OpenAlex indexes 32 publications with 565 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3000 Mack Rd Ste 100
Fairfield, OH 450145335
Telephone
513-751-4222Provider last certified this registry record 6 Aug 2025.
Clinical trials
- The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG
Sponsor: University of Cincinnati
- Recurrent Atrial Fibrillation
Sponsor: University of Cincinnati
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202510 payments
- Medtronic, Inc.Program year20252 payments
- Edwards Lifesciences CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
50.4%Beta blocker20.8%Metoprolol Succinate61%Metoprolol Tartrate25%Carvedilol14%Part D≥61 patientsAntiarrhythmic10.2%Amiodarone Hcl75%Flecainide Acetate25%Part D≥47 patients+ 6 more classes in this area
Blood & clotting
42.1%Factor Xa inhibitor24.7%Eliquis81%Xarelto19%Part D≥85 patientsVitamin K antagonist9.2%Warfarin Sodium100%Part D≥32 patients+ 2 more classes in this area
Metabolism & gastrointestinal
7.5%Proton pump inhibitor4%Pantoprazole Sodium100%Part D≥32 patientsSGLT2 inhibitor3.5%Jardiance100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Abstract 11560: Long Term Outcome of Transfemoral Device Implantation: Success Rate, Pitfalls and Complications
Circulation
2019 - Abstract 11554: Atrial Fibrillation Ablation Outcome in Congenitally Corrected Transposition of Great Arteries
Circulation
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”